Antibody Protein ELISA Kit from MyBioSource header Telephone 1.858.633.0165          
1.855.MyBioSource
Fax 1.858.633.0166    Email sales@mybiosource.com 
tel/fax
menu1 Home Products Ordering Company Help menu7
bottom
   MyBioSource rightarrow Recombinant Protein rightarrow VEGFR2 / Flk-1 / CD309 / KDR  rightarrow LOG IN  rightarrow MY ACCOUNT  rightarrow CART CONTENTS  rightarrow CHECKOUT 
horiz bar
MyBioSource Menu separator
separator
ELISA Kit ELISA Kit
CLIA Kit CLIA Kit
PCR Kit PCR Kit
Monoclonal Antibody Monoclonal Antibody
Polyclonal Antibody Polyclonal Antibody
Secondary Antibody Secondary Antibody
Antigen Antigen
Biochemical Biochemical
cDNA Clone cDNA Clone
siRNA siRNA
Peptide Peptide
Recombinant/Purified Protein Rec./Purified Protein

Custom ELISA Kit Custom ELISA Kit
Custom Protein Custom Protein
Custom Antibody Custom Antibody
Antibody Matched Pairs Antibody Matched Pairs
Antibody & Corresponding Blocking Peptide Pairs Antibody Peptide Pairs
Phospho-Specific Antibodies Phospho Antibodies
Products by Disease Products by Disease
Products by Pathway Products by Pathway
Products by Tissue Products by Tissue

arrow Advanced Search
arrow Submit Technical Q&A
arrow International Distributors
arrow Contact Us
separator
Our Best Sellers moreseparator
separator
 • BAT3-BAG6 Antibody
 • S-100 Antibody
 • GLP-1 ELISA Kit
 • Synaptotagmin (SYT1) Antibody
 • C-C motif chemokine 3 protein (Ccl3) Recombinant Protein
 • TECK ELISA Kit
 • A Disintegrin and Metalloprotease 15 (ADAM15) ELISA Kit
 • Procollagen Type I C Terminal Propeptide (PICP) ELISA Kit
 • granulysin (GNLY) ELISA Kit
 • Interleukin 11 (IL11) ELISA Kit
 • 25-hydroxy vitamin D3 (25 HVD3) ELISA Kit
 • Mannan-binding lectin serine protease 1 (Masp1) Recombinant Protein
 • Exendin 4 (EXENDIN-4) ELISA Kit
 • Extracellular glycoprotein lacritin (LACRT) Recombinant Protein
 downarrow more ...
separator
separator
DatasheetFull DatasheetPrinter Friendly DatasheetPrint This DatasheetAdd to Compare ListHave Questions? Ask UsRequest for a Quotation today

VEGFR2 / Flk-1 / CD309 / KDR recombinant protein

Scan QR to view Datasheet Catalog #    MBS2546580
SDS-PAGE
Unit / Price
0.05 mg  /  $445 +1 FREE 8GB USB
0.1 mg  /  $635 +1 FREE 8GB USB
 
 Go to:   rightarrow  Product Names   rightarrow Product Info   rightarrow Accession #s   rightarrow Product Desc   rightarrow Diseases/Tissues/Pathways   rightarrow Applications   rightarrow References 
 Product Name   

VEGFR2 / Flk-1 / CD309 / KDR, Recombinant Protein

★Popular Item★
 Also Known As   

Recombinant Human VEGFR2 / Flk-1 / CD309 / KDR Protein (His tag)

 Product Synonym Names    CD309, FLK1, VEGFR, VEGFR2, KDR
 Product Gene Name   

VEGFR2 / Flk-1 / CD309 / KDR recombinant protein

[Similar Products]
 Research Use Only    For Research Use Only. Not for use in diagnostic procedures.
Table BarTOPTable Bar
 MBS2546580 Technical Datasheet    Technical Datasheet PDF
 OMIM    EU826563 mRNA
 3D Structure    ModBase 3D Structure for P35968
Section Bar
 Host    Human Cells
Section Bar
 Purity/Purification    > 97 % as determined by SDS-PAGE
 Form/Format    Lyophilized from sterile PBS, pH 7.4, 7.5% mannitol.
Section Bar
 Source    Human
 Predicted N Terminal    Ala 20
 Endotoxin    < 1.0 EU per ug of the protein as determined by the LAL method
 Bio-Activity    1.- Using the Octet RED systerm, the affinity constant (Kd)of human VEGFR2-his bound to biotinylated human VEGF165 was 5.9 nM.
2.- Measured by its ability to inhibit the VEGF- dependetn profilerration of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 10-50 ug/mL in the presence of 10 ng/mL recombinant human VEGF165.
 Reconstitution    It is recommended that sterile water (200 uL) be added to the vial to prepare a stock solution of 0.25 mg/mL.
Concentration is measured by UV-Vis.
 Stability    Samples are stable for up to twelve months from date of receipt at -70C .
Section Bar
 Preparation and Storage    Store it under sterile conditions at -20c to -80C. It is recommended that the protein be aliquot and be used as soon as possible. Avoid repeated freeze- thaw cycles.
 ISO Certification    Manufactured in an ISO 9001:2008 Certified Laboratory.
 Other Notes    Small volumes of VEGFR2 / Flk-1 / CD309 / KDR recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Table BarTOPTable Bar
 

Related Product Information for VEGFR2 / Flk-1 / CD309 / KDR recombinant protein

   Background: VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.

Description: A DNA sequence encoding the extracellular domain of human VEGFR2 (NP_002244.1) (Met 1-Glu 764) was fused with a polyhistidine tag at the C-terminus.
 Application Notes for VEGFR2 / Flk-1 / CD309 / KDR recombinant protein    The secreted recombinant human VEGFR2 consists of 756 amino acids and predicts a molecular mass of 84.6 kDa. The apparent molecular mass of rhVEGFR2 is approximatly 120-130 in SDS-PAGE under reducing conditions.
Section Bar
 SDS-PAGE of VEGFR2 / Flk-1 / CD309 / KDR recombinant protein    VEGFR2 / Flk-1 / CD309 / KDR recombinant protein SDS-PAGE image
Table BarTOPTable Bar
NCBI/Uniprot data below describe general gene information for VEGFR2 / Flk-1 / CD309 / KDR. It may not necessarily be applicable to this product.
 NCBI GI #    11321597
 NCBI GeneID    3791
 NCBI Accession #    NP_002244.1 [Other Products]
 NCBI GenBank Nucleotide #    NM_002253.2 [Other Products]
Section Bar
 UniProt Primary Accession #    P35968 [Other Products]
 UniProt Secondary Accession #    O60723; Q14178; A2RRS0; B5A925; C5IFA0 [Other Products]
 UniProt Related Accession #    P35968 [Other Products]
Table BarTOPTable Bar
 NCBI Official Full Name    vascular endothelial growth factor receptor 2
 NCBI Official Synonym Full Names    kinase insert domain receptor
 NCBI Official Symbol    KDR [Similar Products]
 NCBI Official Synonym Symbols   
FLK1; CD309; VEGFR; VEGFR2
[Similar Products]
 NCBI Protein Information    vascular endothelial growth factor receptor 2
 UniProt Protein Name    Vascular endothelial growth factor receptor 2
 UniProt Synonym Protein Names   
Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD_antigen: CD309
 UniProt Gene Name    KDR [Similar Products]
 UniProt Synonym Gene Names    FLK1; VEGFR2; VEGFR-2; FLK-1; KDR [Similar Products]
Section Bar
 NCBI Summary for VEGFR2 / Flk-1 / CD309 / KDR    Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]
Section Bar
 UniProt Comments for VEGFR2 / Flk-1 / CD309 / KDR    Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
Table BarTOPTable Bar
 Research Articles on VEGFR2 / Flk-1 / CD309 / KDR    1. The expression levels of two target genes, Myb and VEGFR2, were affected significantly by miR-16, while glucose administration inhibited miR-16 expression and enhanced tumor cell proliferation and migration.
Table BarTOPTable Bar
 Precautions    All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
 Disclaimer    While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Table BarTOPTable Bar
Products associated with VEGFR2 / Flk-1 / CD309 / KDR recombinant proteinPathways associated with VEGFR2 / Flk-1 / CD309 / KDR recombinant protein
 Reference Product  PubMed Publications
 VEGFA recombinant protein  >225 publications with VEGFR2 / Flk-1 / CD309 / KDR and VEGFA
 FLT1 recombinant protein  >173 publications with VEGFR2 / Flk-1 / CD309 / KDR and FLT1
 SRC recombinant protein  >54 publications with VEGFR2 / Flk-1 / CD309 / KDR and SRC
 FLT4 recombinant protein  >37 publications with VEGFR2 / Flk-1 / CD309 / KDR and FLT4
 VEGFC recombinant protein  >29 publications with VEGFR2 / Flk-1 / CD309 / KDR and VEGFC
 NRP1 recombinant protein  >15 publications with VEGFR2 / Flk-1 / CD309 / KDR and NRP1
 COL18A1 recombinant protein  >10 publications with VEGFR2 / Flk-1 / CD309 / KDR and COL18A1
 GRB2 recombinant protein  >6 publications with VEGFR2 / Flk-1 / CD309 / KDR and GRB2
 CRK recombinant protein  >5 publications with VEGFR2 / Flk-1 / CD309 / KDR and CRK
 CTNNB1 recombinant protein  >5 publications with VEGFR2 / Flk-1 / CD309 / KDR and CTNNB1
 Products by Pathway  Pathway Diagram
 Angiogenesis Pathway antibodies  Angiogenesis Pathway Diagram
 Cardiac Progenitor Differentiation Pathway antibodies  Cardiac Progenitor Differentiation Pathway Diagram
 Cytokine-cytokine Receptor Interaction Pathway antibodies  Cytokine-cytokine Receptor Interaction Pathway Diagram
 Cytokine-cytokine Receptor Interaction Pathway antibodies  Cytokine-cytokine Receptor Interaction Pathway Diagram
 Endocytosis Pathway antibodies  Endocytosis Pathway Diagram
 Endocytosis Pathway antibodies  Endocytosis Pathway Diagram
 Focal Adhesion Pathway antibodies  Focal Adhesion Pathway Diagram
 Focal Adhesion Pathway antibodies  Focal Adhesion Pathway Diagram
 Focal Adhesion Pathway antibodies  Focal Adhesion Pathway Diagram
 HIF-2-alpha Transcription Factor Network Pathway antibodies  HIF-2-alpha Transcription Factor Network Pathway Diagram
Diseases associated with VEGFR2 / Flk-1 / CD309 / KDR recombinant proteinOrgans/Tissues associated with VEGFR2 / Flk-1 / CD309 / KDR recombinant protein
 Disease Name  Pubmed Publications
 Neoplasms Antibodies  >623 publications with VEGFR2 / Flk-1 / CD309 / KDR and Neoplasms
 Neovascularization, Pathologic Antibodies  >369 publications with VEGFR2 / Flk-1 / CD309 / KDR and Neovascularization, Pathologic
 Heart Diseases Antibodies  >138 publications with VEGFR2 / Flk-1 / CD309 / KDR and Heart Diseases
 Myocardial Ischemia Antibodies  >127 publications with VEGFR2 / Flk-1 / CD309 / KDR and Myocardial Ischemia
 Adenocarcinoma Antibodies  >110 publications with VEGFR2 / Flk-1 / CD309 / KDR and Adenocarcinoma
 Neoplasms, Experimental Antibodies  >102 publications with VEGFR2 / Flk-1 / CD309 / KDR and Neoplasms, Experimental
 Breast Neoplasms Antibodies  >85 publications with VEGFR2 / Flk-1 / CD309 / KDR and Breast Neoplasms
 Inflammation Antibodies  >83 publications with VEGFR2 / Flk-1 / CD309 / KDR and Inflammation
 Drug Toxicity Antibodies  >81 publications with VEGFR2 / Flk-1 / CD309 / KDR and Drug Toxicity
 Atherosclerosis Antibodies  >73 publications with VEGFR2 / Flk-1 / CD309 / KDR and Atherosclerosis
 Organ/Tissue Name  Pubmed Publications
 Vascular Antibodies  >1955 publications with VEGFR2 / Flk-1 / CD309 / KDR and Vascular
 Embryonic Tissue Antibodies  >239 publications with VEGFR2 / Flk-1 / CD309 / KDR and Embryonic Tissue
 Bone Antibodies  >231 publications with VEGFR2 / Flk-1 / CD309 / KDR and Bone
 Muscle Antibodies  >211 publications with VEGFR2 / Flk-1 / CD309 / KDR and Muscle
 Heart Antibodies  >174 publications with VEGFR2 / Flk-1 / CD309 / KDR and Heart
 Liver Antibodies  >165 publications with VEGFR2 / Flk-1 / CD309 / KDR and Liver
 Lung Antibodies  >161 publications with VEGFR2 / Flk-1 / CD309 / KDR and Lung
 Placenta Antibodies  >110 publications with VEGFR2 / Flk-1 / CD309 / KDR and Placenta
 Brain Antibodies  >98 publications with VEGFR2 / Flk-1 / CD309 / KDR and Brain
 Kidney Antibodies  >88 publications with VEGFR2 / Flk-1 / CD309 / KDR and Kidney
Table BarTOPTable Bar
horiz bar
 SSL   Follow us on Facebook Follow us onTwitter Follow us on Google Plus Connect us on LinkedIn Subscribe to our RSS Feed for latest products and special promotions